- JP-listed companies
- PhoenixBio Co.,Ltd.
- Financials
- EBITDA margin (%)
PhoenixBio Co.,Ltd.【JP:6190】
Market cap
¥1.8B
P/E ratio
16.8x
Phoenix Bio provides pharmaceutical testing services using PXB mice with human liver cells to help drug companies predict how medicines work in people.
| Period End | EBITDA margin (%) | YoY (%) |
|---|---|---|
| Mar 31, 2025 | -7.4 | -449.24% |
| Mar 31, 2024 | 2.1 | -91.56% |
| Mar 31, 2023 | 25.1 | -507.85% |
| Mar 31, 2022 | -6.1 | -71.88% |
| Mar 31, 2021 | -21.8 | +206.82% |
| Mar 31, 2020 | -7.1 | -68.97% |
| Mar 31, 2019 | -22.9 | -15.21% |
| Mar 31, 2018 | -27.1 | -298.91% |
| Mar 31, 2017 | 13.6 | -22.08% |
| Mar 31, 2016 | 17.5 | +113.09% |
| Mar 31, 2015 | 8.2 |